ew techniques for reducing intraocular pressure spike after intravitreal injection of bevacizumab

Not Applicable

Completed

• Conditions: Eye Diseases; Intraocular pressure after bevacizumab intravitreal injection

• Registration Number: ISRCTN14424997
• Lead Sponsor: Eye Clinic, Univertsity of Turin

Brief Summary

2020 Results article in https://doi.org/10.2147/OPTH.S263474 (added 18/08/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-05-31
• Study Start: 2019-07-24
• Last Update Posted: 28 August 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

1. Age between 18 to 99 years old
2. Indication for intravitreal injection of anti-VEGF drug (bevacizumab)
3. Absence of contraindications to the execution of intravitreal injection (systemic or local conditions that make the injective treatment not indicated)
4. Possibility of expressing informed consent to participation in the study

Exclusion Criteria

1. Prior intravitreal injection into the eye being studied in the previous month
2. Prior history of endophthalmitis following intravitreal injection
3. Prior intravitreal steroid injection in the previous 6 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Variation of the post-injection IOP with the different injection techniques measured using Goldmann applanation tonometry 10 min before and 10 min after injection.

Secondary Outcome Measures

Name	Time	Method
1. Percentage of post- intravitreal injection IOP spikes with IOP =40 mmHg in study arms measured using Goldmann applanation tonometry 10 min before and 10 min after injection<br>2. Phakia/pseudophakia status<br>3. Previous diagnosis of glaucoma<br>4. Ophthalmic pathology for which indication was given to intravitreal injection<br>5. The percentage of adverse events was also evaluated